Isatuximab-irfc is a monoclonal antibody directed against CD38 that elicits antibody-dependent cell-mediated cytotoxicity. This is an adaptive immune response that occurs when immune cells recognize antibody-coated cancer cells for destruction and trigger cell lysis.
The drug is indicated for the treatment of adult patients with multiple myeloma.